Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496–507.

Article  PubMed  Google Scholar 

Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1–20.

Article  CAS  PubMed  Google Scholar 

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325–30.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Eikema D-J, Iacobelli S, Koster L, Nahi H, Stoppa A-M, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103:890–7.

CAS  PubMed  PubMed Central  Google Scholar 

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–4.

Article  PubMed  PubMed Central  Google Scholar 

Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:1–10.

Article  Google Scholar 

Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019;36:32–39.

Article  PubMed  Google Scholar 

Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232–44.

Article  CAS  PubMed  Google Scholar 

Cohen YC, Morillo D, Gatt ME, Sebag M, Kim K, Min C-K, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8002–8002.

Article  Google Scholar 

Garcés J-J, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020;34:589–603.

Article  PubMed  Google Scholar 

Termini R, Žihala D, Terpos E, Perez-Montaña A, Jelínek T, Raab M, et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin Cancer Res J Am Assoc Cancer Res. 2022;28:4771–81.

Article  CAS  Google Scholar 

Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma. J Clin Oncol. 2023;41:1383–92.

Article  CAS  PubMed  Google Scholar 

Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87–94.

Article  CAS  PubMed  Google Scholar 

Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016;97:93–100.

Article  CAS  PubMed  Google Scholar 

de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, et al. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J. 2016;6:e426.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rao M, et al. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol. 2020;44:838–48.

Article  PubMed  PubMed Central  Google Scholar 

Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol. 2003;122:728–44.

Article  CAS  PubMed  Google Scholar 

Ryu D, Kim SJ, Hong Y, Jo A, Kim N, Kim H-J, et al. Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clin Cancer Res. 2020;26:935–44.

Article  CAS  PubMed  Google Scholar 

Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371–.e18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007;26:3113–21.

Article  CAS  PubMed  Google Scholar 

Qie S, Sang N. Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target. J Exp Clin Cancer Res. 2022;41:161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang X, Dong Y. CACNA1C is a prognostic predictor for patients with ovarian cancer. J Ovarian Res. 2021;14:88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel AJ, Tan T-M, Richter AG, Naidu B, Blackburn JM, Middleton GW. A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications. Br J Cancer. 2022;126:238–46.

Article  CAS  PubMed  Google Scholar 

Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8:419–29.

Article  CAS  PubMed  Google Scholar 

Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, et al. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun. 2022;13:6820.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Song S, Zhang J, Su Q, Zhang W, Jiang Y, Fan G, et al. Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia. Br J Cancer. 2021;124:1843–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36:288–91.

Article  PubMed  Google Scholar 

Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, et al. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 2018;33:706–.e9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Chen D, Liu H, Yang K. Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma. Cell Death Dis. 2019;10:1–16.

Google Scholar 

Kong F, Deng X, Kong X, Du Y, Li L, Zhu H, et al. ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 2018;37:5982–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Danhof S, Rasche L, Mottok A, Steinmüller T, Zhou X, Schreder M, et al. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Ann Hematol. 2021;100:1537–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127:4198–212.

Article  CAS  PubMed  Google Scholar 

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387:495–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, et al. CD70: an emerging target in cancer immunotherapy. Pharmacol Ther. 2015;155:1–10.

Article  CAS  PubMed  Google Scholar 

Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41:12.